Unal, C. Et Al. 2023. Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye. Eurasian Journal of Medicine and Oncology , vol.7, no.3 , 232-242.

Unal, C., Selcuk, N. A., Biricik, F. S., Alan, O., Ordu, C., Selvi, O., ... Sakin, A.(2023). Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye. Eurasian Journal of Medicine and Oncology , vol.7, no.3, 232-242.

Unal, Caglar Et Al. "Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye," Eurasian Journal of Medicine and Oncology , vol.7, no.3, 232-242, 2023

Unal, Caglar Et Al. "Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye." Eurasian Journal of Medicine and Oncology , vol.7, no.3, pp.232-242, 2023

Unal, C. Et Al. (2023) . "Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye." Eurasian Journal of Medicine and Oncology , vol.7, no.3, pp.232-242.

@article{article, author={Caglar Unal Et Al. }, title={Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye}, journal={Eurasian Journal of Medicine and Oncology}, year=2023, pages={232-242} }